Selected article for: "cardiovascular disease and hospital death"
Author: Quan Li; Zanxia Cao; Proton Rahman
Title: Genetic Variability of Human Angiotensin-Converting Enzyme 2 (hACE2) Among Various Ethnic Populations
  • Document date: 2020_4_15
    • ID: bbn1tfq5_3
    Snippet: Differences among the host, particularly the sex of the patient and presence of selected co-morbid diseases and immunosuppressive state have been identified as risk factors from severe Covid-192,3. Pre-existing medical conditions have been associated with increased prevalence of death including: cardiovascular disease (13.2%); diabetes (9.2%); chronic respiratory disease (8.0%); hypertension (8.4%) and recent diagnosis of cancer (7.6%) 4. Specifi.....
    Document: Differences among the host, particularly the sex of the patient and presence of selected co-morbid diseases and immunosuppressive state have been identified as risk factors from severe Covid-192,3. Pre-existing medical conditions have been associated with increased prevalence of death including: cardiovascular disease (13.2%); diabetes (9.2%); chronic respiratory disease (8.0%); hypertension (8.4%) and recent diagnosis of cancer (7.6%) 4. Specifically, hypertensive patients had a hazard ratio of 1.70 for death 5 and 3.05 for in-hospital mortality 4. An increased association with the use of angiotensinconverting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) has been reported for severe Covid-19 cases6. A biologically plausible link between SARS-CoV-2 infections and ACE inhibition has been proposed 7.

    Search related documents:
    Co phrase search for related documents
    • ACE inhibition and enzyme inhibitor: 1, 2, 3, 4
    • ACEIs enzyme inhibitor and enzyme inhibitor: 1, 2
    • arb II receptor blocker and cardiovascular disease: 1
    • arb II receptor blocker and enzyme inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • arb II receptor blocker and hazard ratio: 1, 2
    • arb II receptor blocker and hospital mortality: 1, 2
    • arb II receptor blocker and II receptor blocker: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • cardiovascular disease and chronic respiratory disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiovascular disease and co morbid disease: 1, 2, 3, 4, 5, 6
    • cardiovascular disease and enzyme inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cardiovascular disease and hazard ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiovascular disease and hospital mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiovascular disease and hypertensive patient: 1, 2
    • cardiovascular disease and II receptor blocker: 1, 2, 3
    • cardiovascular disease include and chronic respiratory disease: 1
    • cardiovascular disease include and hospital mortality: 1
    • chronic respiratory disease and enzyme inhibitor: 1
    • chronic respiratory disease and hazard ratio: 1, 2, 3, 4, 5, 6, 7, 8
    • chronic respiratory disease and hospital mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20